Key result
Mechanical double-valve replacement achieves event-free 16-month survival in severe mucopolysaccharidosis VI.
Case Report (n=1)
No
Answers are grounded in this paper and cite their sources.
Double-valve replacement can be successfully performed in adult patients with mucopolysaccharidosis VI when supported by meticulous perioperative airway and respiratory management, although a preexisting tracheostomy does not completely eliminate the risk of postoperative pneumonia.
INTRODUCTION: Mucopolysaccharidosis VI (MPS VI) is a rare lysosomal storage disorder involving progressive systemic manifestations, including valvular heart disease. Double-valve replacement (DVR) for MPS VI is rarely reported, and its perioperative management is challenging because of airway and respiratory involvement. This report describes a patient with MPS VI successfully treated with DVR, highlighting perioperative strategies that contributed to a favorable outcome. CASE PRESENTATION: A 37-year-old woman with MPS VI (height: 105 cm, weight: 26 kg), who underwent hematopoietic stem cell transplantation and permanent tracheostomy, developed dyspnea associated with aortic regurgitation (AR) and mitral regurgitation (MR). Eventually, she underwent elective DVR along with enzyme replacement therapy. Despite careful airway and respiratory management, pneumonia occurred postoperatively but resolved with antibiotics. She was discharged in good condition on POD 43. At 16 months after surgery, she remained free of heart failure and respiratory failure. CONCLUSIONS: DVR can be performed successfully in adults with MPS VI. Careful perioperative airway and respiratory management is essential, and a preexisting tracheostomy may help secure the upper airway but does not eliminate postoperative pulmonary risk.
No takes yet. Share an insight, caveat, or question.
Hoshina et al. (2026) conducted a case report in Mucopolysaccharidosis VI (MPS VI) with moderate-to-severe aortic regurgitation and moderate mitral regurgitation (n=1). Elective surgical double-valve replacement (17-mm St. Jude Medical Regent mechanical aortic valve and 21-mm St. Jude Medical standard mechanical mitral valve) combined with weekly galsulfase enzyme replacement therapy and perioperative airway management was evaluated on Postoperative recovery, prosthetic valve function, and freedom from heart failure and respiratory failure at 16 months. Elective mechanical double-valve replacement in a 37-year-old woman with mucopolysaccharidosis VI resulted in discharge on POD 43 and 16-month survival free of heart or respiratory failure.
Synapse has enriched 10 related papers. Consider them for comparative context: